209 related articles for article (PubMed ID: 24355918)
1. The search for treatments to reduce chemotherapy-induced peripheral neuropathy.
Pachman DR; Loprinzi CL; Grothey A; Ta LE
J Clin Invest; 2014 Jan; 124(1):72-4. PubMed ID: 24355918
[TBL] [Abstract][Full Text] [Related]
2. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.
Coriat R; Alexandre J; Nicco C; Quinquis L; Benoit E; Chéreau C; Lemaréchal H; Mir O; Borderie D; Tréluyer JM; Weill B; Coste J; Goldwasser F; Batteux F
J Clin Invest; 2014 Jan; 124(1):262-72. PubMed ID: 24355920
[TBL] [Abstract][Full Text] [Related]
3. Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca
Karlsson JOG; Jynge P
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673932
[TBL] [Abstract][Full Text] [Related]
4. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
6. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
Smith EM; Pang H; Ye C; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Le-Lindqwister N; Fadul CE; Loprinzi C; Shapiro CL;
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26603828
[TBL] [Abstract][Full Text] [Related]
7. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
[TBL] [Abstract][Full Text] [Related]
9. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
Hopkins HL; Duggett NA; Flatters SJL
Curr Opin Support Palliat Care; 2016 Jun; 10(2):119-128. PubMed ID: 27054288
[TBL] [Abstract][Full Text] [Related]
11. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP.
Streckmann F; Balke M; Lehmann HC; Rustler V; Koliamitra C; Elter T; Hallek M; Leitzmann M; Steinmetz T; Heinen P; Baumann FT; Bloch W
BMC Cancer; 2018 Jan; 18(1):62. PubMed ID: 29316888
[TBL] [Abstract][Full Text] [Related]
12. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.
Ewertz M; Qvortrup C; Eckhoff L
Acta Oncol; 2015 May; 54(5):587-91. PubMed ID: 25751757
[TBL] [Abstract][Full Text] [Related]
14. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.
Aziz MT; Good BL; Lowe DK
Ann Pharmacother; 2014 May; 48(5):626-32. PubMed ID: 24577146
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review.
Pulvers JN; Marx G
Asia Pac J Clin Oncol; 2017 Dec; 13(6):345-355. PubMed ID: 28653815
[TBL] [Abstract][Full Text] [Related]
16. Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-Induced Peripheral Neuropathy.
Nakagawa T; Kaneko S
Biol Pharm Bull; 2017; 40(7):947-953. PubMed ID: 28674258
[TBL] [Abstract][Full Text] [Related]
17. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
18. Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy.
Kelley MR; Wikel JH; Guo C; Pollok KE; Bailey BJ; Wireman R; Fishel ML; Vasko MR
J Pharmacol Exp Ther; 2016 Nov; 359(2):300-309. PubMed ID: 27608656
[TBL] [Abstract][Full Text] [Related]
19. Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
J Support Oncol; 2006 Feb; 4(2):82-3. PubMed ID: 16499128
[No Abstract] [Full Text] [Related]
20. [Evidence from basic studies on mechanisms and treatment drugs for oxaliplatin-induced peripheral neuropathy].
Egashira N; Kawashiri T; Oishi R
Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):66-70. PubMed ID: 23391544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
